Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

7 Signs of Low Testosterone That Indian Men Routinely Mistake for Normal Aging Symptoms

The Tiredness That Sleep Cannot FixMost men notice it first as an energy problem. They sleep seven or eight hours and wake up feeling like they haven't slept at all. Afternoon crashes arrive earlier. The motivation to get through the evening disappears by 7 PM. This gets filed under stress,…

Times Life

Food Processing Minister Chirag Paswan asks food cos to focus on making quality products

Union Minister Chirag Paswan underscored the potential within India's food processing industry, encouraging businesses to focus on quality to compete in international markets. He raised alarms about the increasing obesity rates among young people, advocating for healthier snack options.

The Economic Times

Women Are Getting Hired More After Losing Weight on GLP-1 Drugs: A New Study Raises Difficult Questions

A new study found GLP-1 drug users hired more after weight loss — but researchers say the finding reflects illegal-in-most-states weight discrimination, not just health gains.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Scientists Just Found Why Middle-Age Belly Fat Suddenly Appears, and It Has to Do with Stem Cells

New research published June 27 found aging-activated stem cells drive middle-age belly fat accumulation. The same visceral fat is linked to heart disease and Alzheimer's risk.

Medical Daily

“GLP-1s are changing obesity care, but they’ve also created unrealistic expectations”—the CEO of the American Council on Exercise on common weight loss misconceptions

Treating GLP-1s as a substitute for lifestyle change is one of the most common mistakes people make, says this industry expert

Fit & Well

Medicare's New $50 GLP-1 Weight-Loss Program Just Launched: Find Out if You Qualify

Medicare's GLP-1 Bridge launched July 1, 2026. Up to 3.8M seniors may qualify for $50/month Wegovy, Zepbound, or Foundayo. Here's the eligibility breakdown.

Medical Daily

Obese adults heart attack risk now similar to slim people thanks to widespread use of statins, study finds

Statins, a cholesterol lowering drug taken by about 8 million people in the UK, could be narrowing the heart attack risk between obese adults and those of a healthy weight

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Four GLP-1 Findings from June 2026 Are Changing the Picture of What These Drugs Actually Do

Four GLP-1 studies published in June 2026 show effects on breast cancer, violence, bone fractures, and physical activity. Here's what each found and what it means for patients.

Medical Daily

New obesity figures highlight the income divide

The number of obese adults in England rose from 26% in 2019 to 30% in 2025, according to a new analysis of 55 million people. Nearly one in three adults are now obese.

The Conversation

About 170,000 people in England expected to die from obesity-linked heart conditions by 2035

British Heart Foundation finds about 45 people a day expected to die over next decade if current trends continue

The Guardian - UK

Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'

Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like long-term adherence and physician conservatism. Biocon's Kiran Mazumdar-Shaw weighed in and urged caution, emphasizing diet and exercise as primary options for non-diabetic, non-obese individuals, citing potential long-term side effects of these…

The Economic Times

Grim Autopsy Details Torture As Morbidly Obese Seven-Year-Old Boy Weighing More Than Two Grown Men Suffers Fatal Agony

A Michigan couple faces murder and child abuse charges after their seven-year-old son died from heart failure linked to extreme obesity, highlighting severe neglect and household dysfunction.

International Business Times UK

'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugs

Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges with weekly injections and conservative doctor prescribing habits as key hurdles. The advent of oral alternatives might boost uptake, suggesting convenience and long-term commitment, rather than price, will drive future acceptance of…

The Economic Times

White House denies Donald Trump is the mystery patient receiving experimental obesity drug: ‘Idiotic question’

White House spokesperson says gossip that Trump is the patient is "baseless speculation."

We Got This Covered

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Did Trump Get Experimental Obesity Drug? Rep Lieu Demands Answers Over FDA's 'Powerful Drug' Given to 'Unidentified 79-Year-Old Man'

Representative Ted Lieu questions the White House about claims that President Trump accessed an experimental obesity drug reserved for the gravely ill, sparking controversy and speculation.

Medical Daily

Medicare's New $50 Weight Loss Drug Program Starts July 1 — but the Fine Print Could Surprise You

Medicare's GLP-1 Bridge starts July 1, 2026, with $50/month copays. But there are major fine-print limitations seniors need to know before signing up. Here's what to check.

International Business Times UK

Trump Linked to Mystery FDA Deal Granting Early Access to Powerful Weight-Loss Drug for Critical Patients

A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide, sparking political and medical controversy amid speculation about the patient's identity.

The Independent UK

White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April

A White House spokesman said theories that President Trump sought the drug were ‘baseless speculation’

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

As Aussie waistlines expand, so do treatment costs

Most adult Australians are actually overweight or obese and that number is rising, research shows, with the problem taking a growing toll on health systems.

Newcastle Herald

'It's not getting better': leading risk factor revealed for ill health and death

Almost 70 per cent of adults in Hunter New England are overweight or obese.

Medical Daily

ENDO 2026 Study Finds Most People Who Stop Ozempic or Tirzepatide for Type 2 Diabetes Eventually Restart Treatment

ENDO 2026 research published June 2026 via ScienceDaily found most GLP-1 users with type 2 diabetes who stop treatment eventually restart, driven by weight regain.

AAP

Health company accused of using fake doctors for sales

Australians with diabetes, heart disease, obesity and menopause paid thousands and spoke with fake doctors who said their lives were at risk, a watchdog claims.

Medical Daily

Ozempic Changed Obesity Treatment Forever — but Experts See a Bigger Medical Revolution Still Coming

A June 20, 2026 ScienceDaily report on a Gastroenterology commentary describes how GLP-1 drugs opened the door to a next era combining drugs, minimally invasive procedures, and precision medicine.

The Independent UK

Kids as young as six are being given weight-loss drugs as a way to curb obesity before it gets too late

About 21 percent of U.S. children between the ages of two and 19 have obesity, according to data from the Centers for Disease Control and Prevention

The Economic Times

Pfizer CFO Dave Denton to leave company in August

Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure raises investor concerns about Pfizer's 2026 forecast and succession plans. The company is preparing to enter the obesity drug market. Pfizer's shares were down in early trading. A search…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

321 stories

ACE

267 stories

the Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.